We are live on ! Find out more
NRXP icon

NRX Pharmaceuticals
NRXP

20 hedge funds and large institutions have $44.7M invested in NRX Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more capital invested

Capital invested by funds: $44.1M → $44.7M (+$661K)

0% more funds holding

Funds holding: 20 → 20 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0.02% less ownership

Funds ownership: 4.98% → 4.96% (-0.02%)

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Holders
20
Holders Change
–
Holders Change %
0%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MSU
Mizuho Securities USA
New York
+$1.24M
2
KPF
K2 Principal Fund
Ontario, Canada
+$595K
3
CI
Cowen Inc
New York
+$320K
4
WAM
Weiss Asset Management
Massachusetts
+$277K

Top Sellers

Rank Fund Capital Flow
1
LIM
Longfellow Investment Management
Massachusetts
-$972K
2
HCMT
Highland Capital Management (Texas)
Texas
-$516K
3
BI
Bulldog Investors
New Jersey
-$485K
4
KIM
Karpus Investment Management
New York
-$423K
5
HIM
HGC Investment Management
Ontario, Canada
-$117K
Name Holding Trade Value Shares
Change 		Change in
Stake
HIM
1
HGC Investment Management
Ontario, Canada
$4.79M -$117K -1,159 -2%
PAMP
2
Polar Asset Management Partners
Ontario, Canada
$4.78M – – –
OAM
3
Oxford Asset Management
United Kingdom
$4.57M – – –
Bank of Montreal
4
Bank of Montreal
Ontario, Canada
$3.59M – – –
BFM
5
Boothbay Fund Management
New York
$3.06M – – –
PC
6
Periscope Capital
Ontario, Canada
$2.57M -$2.02K -20 -0.1%
WCMNY
7
Westchester Capital Management (New York)
New York
$2.5M – – –
RCM
8
Rivernorth Capital Management
Florida
$2.45M – – –
BI
9
Bulldog Investors
New Jersey
$2.41M -$485K -4,800 -17%
KIM
10
Karpus Investment Management
New York
$2.13M -$423K -4,190 -17%
WRBC
11
W.R. Berkley Corp
Connecticut
$2.07M – – –
AA
12
AQR Arbitrage
Connecticut
$2M – – –
KPF
13
K2 Principal Fund
Ontario, Canada
$1.97M +$595K +5,890 +44%
GCL
14
Glazer Capital LLC
New York
$1.71M -$48.7K -482 -3%
YCM
15
Yakira Capital Management
Connecticut
$1.68M – – –
MSU
16
Mizuho Securities USA
New York
$1.25M +$1.24M +12,304 New
BCM
17
Basso Capital Management
Connecticut
$547K – – –
CI
18
Cowen Inc
New York
$323K +$320K +3,163 New
WAM
19
Weiss Asset Management
Massachusetts
$280K +$277K +2,741 New
BCM
20
Bluefin Capital Management
New York
$39K – – –
LIM
21
Longfellow Investment Management
Massachusetts
– -$972K -9,707 Closed
HCMT
22
Highland Capital Management (Texas)
Texas
– -$516K -5,150 Closed
Walleye Trading
23
Walleye Trading
New York
– -$3K -30 Closed

NRXP Hedge Fund Activity: Q4 2018 in Review

20 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q4 2018, worth a combined $44.7M — up 1.5% from $44.1M a quarter earlier.

Fund positioning in NRXP was balanced in Q4 2018: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 5 trimmed.

The largest buyer was Mizuho Securities USA, opening a new position worth an estimated $1.24M. The largest seller was Longfellow Investment Management, exiting entirely with an estimated $972K sold.

  • 20 institutional investors held NRX Pharmaceuticals (NRXP) as of Q4 2018, unchanged from Q3 2018.
  • Funds reported $44.7M of NRX Pharmaceuticals stock for Q4 2018, up 1.5% quarter-over-quarter.
  • 3 funds opened new NRX Pharmaceuticals positions in Q4 2018 and 3 closed out, a net change of 0 holders.
  • The largest NRX Pharmaceuticals buyer in Q4 2018 was Mizuho Securities USA, an estimated $1.24M added.
  • The largest NRX Pharmaceuticals seller in Q4 2018 was Longfellow Investment Management, an estimated $972K sold.

Based on aggregated 13F filings for Q4 2018.